ADAP Stock Financial Analysis - Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) (NasdaqCM) Stock

Overview

Adaptimmune Therapeutics plc is a biotechnology company based in the United Kingdom, primarily engaged in the development of novel cancer immunotherapy products. With a focus on leveraging its proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform, Adaptimmune aims to harness the power of the body’s own immune system to target and destroy cancer cells. A significant area of their work includes engineering T-cells to enhance their affinity to cancer cells in solid tumors, which are notoriously difficult to treat. Key projects involve multiple ongoing clinical trials targeting different cancer indications, including sarcoma, melanoma, and ovarian cancer. This strategic focus positions Adaptimmune as a notable player in the evolving landscape of cell-based cancer therapies.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The revenue for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is 65.08 MM.
The operating income for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is -147.87 MM.
The net income for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is -169.76 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30	65.08	-147.87	-169.76
2025-03-31	179.64	-47.22	-69.89
2024-12-31	178.03	-52.41	-70.81
2024-09-30	175.04	-37.75	-44.52
2024-06-30	141.46	-76.87	-72.50
2024-03-31	18.36	-187.38	-163.41
2023-12-31	60.28	-130.69	-113.87
2023-09-30	71.08	-113.13	-95.20
2023-06-30	70.77	-102.32	-91.02
2023-03-31	71.17	-104.25	-114.16
2022-12-31	27.15	-163.97	-165.46
2022-09-30	17.54	-179.59	-175.06
2022-06-30	11.73	-178.78	-176.04
2022-03-31	9.29	-174.34	-170.59
2021-12-31	6.15	-162.25	-158.09
2021-09-30	6.23	-156.90	-155.84
2021-06-30	6.22	-150.59	-148.88
2021-03-31	3.63	-141.53	-139.69
2020-12-31	3.96	-133.41	-130.09
2020-09-30	3.18	-126.25	-122.84

Income Statement: EPS

The earnings per share basic for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is -0.66.
The earnings per share diluted for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is -0.65.

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30	-0.66	-0.65
2025-03-31	-0.27	-0.29
2024-12-31	-0.28	-0.30
2024-09-30	-0.18	-0.15
2024-06-30	-0.30	-0.30
2024-03-31	-0.74	-0.72
2023-12-31	-0.57	-0.54
2023-09-30	-0.51	-0.53
2023-06-30	-0.54	-0.54
2023-03-31	-0.70	-0.71
2022-12-31	-1.03	-1.02
2022-09-30	-1.10	-1.10
2022-06-30	-1.12	-1.12
2022-03-31	-1.09	-1.07
2021-12-31	-1.01	-1.02
2021-09-30	-1.00	-1.00
2021-06-30	-0.96	-0.96
2021-03-31	-0.93	-0.93
2020-12-31	-0.91
2020-09-30	-0.94	-0.94

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is -190.03 MM.
The cash from investing activities for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is 1.79 MM.
The cash from financing activities for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is 1.34 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-190.03	1.79	1.34
2025-03-31	-107.85	-17.44	24.19
2024-12-31	-73.21	-58.95	78.75
2024-09-30	-53.68	1.08	78.82
2024-06-30	-44.39	124.40	54.42
2024-03-31	-135.55	127.84	29.92
2023-12-31	-140.88	176.54	0.88
2023-09-30	-124.16	129.29	2.21
2023-06-30	-127.16	100.84	3.06
2023-03-31	-124.65	142.25	13.03
2022-12-31	-141.77	89.14	12.87
2022-09-30	-9.88	39.69	11.52
2022-06-30	-6.92	45.69	10.20
2022-03-31	2.87	49.26	2.79
2021-12-31	10.73	75.80	3.29
2021-09-30	-152.41	111.90	3.36
2021-06-30	-123.53	49.47	3.69
2021-03-31	-116.99	-185.22	249.14
2020-12-31	-53.59	-278.92	340.05
2020-09-30	-36.90	-262.85	339.93

Valuation Metrics : PE, PriceToBook, PriceToTBV

The p/book for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is -1.67.
The p/tbv for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is -1.52.

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30		-1.67	-1.52
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31	-1.09	2.20
2022-12-31		2.11	2.12
2022-09-30		1.23	1.24
2022-06-30	-1.61	1.68	1.69
2022-03-31	-2.04	1.57	1.58
2021-12-31	-3.77	2.44	2.45
2021-09-30	-5.42	2.90	2.92
2021-06-30
2021-03-31	-1.91	0.87	0.87
2020-12-31	-2.05	0.78	0.78
2020-09-30	-2.17	0.71	0.71

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

The ebit/ev for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is -1.41.
The ebit (3y)/ev for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is -1.61.

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30	-1.41	-1.61
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31	-2.26	-2.18
2022-12-31	-1.08	-0.94
2022-09-30	-2.27	-1.96
2022-06-30	-0.92	-0.80
2022-03-31	-0.91	-0.84
2021-12-31	-0.29	-0.26
2021-09-30	-0.20	-0.18
2021-06-30
2021-03-31	-0.59	-0.54
2020-12-31	-0.62	-0.58
2020-09-30	-0.65	-0.63

Management Effectiveness

The roa for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is -0.22.
The roe for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is -0.73.
The roic for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is -6.20.
The croic for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is -8.91.
The ocroic for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is -9.56.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.22	-0.73	-6.20	-8.91	-9.56
2025-03-31	-0.27	-2.91	-0.82	-0.63	-0.85
2024-12-31	-0.16	-1.13	-0.29	0.17	-0.35
2024-09-30	-0.24	-0.82	-0.50	0.94	-0.31
2024-06-30	-0.57	-1.95	-3.40	0.46	-2.82
2024-03-31	-0.35	-1.39	-1.76	0.58	-2.18
2023-12-31	-0.29	-0.84	-0.84	0.11	-1.09
2023-09-30	-0.23	-0.64	-0.59	-0.13	-0.83
2023-06-30	-0.29	-0.80	-0.59	-0.13	-0.83
2023-03-31	-0.39	-1.01	-1.07	0.28	-1.17
2022-12-31	-0.50	-0.73	-1.29	0.27	-0.07
2022-09-30	-0.50	-0.73	-1.29	0.27	-0.07
2022-06-30	-0.44	-0.61	-1.06	0.27	-0.04
2022-03-31	-0.38	-0.51	-0.90	0.29	0.02
2021-12-31	-0.35	-0.46	-0.68	0.39	-0.57
2021-09-30	-0.31	-0.40	-0.58	-0.14	-0.41
2021-06-30	-0.29	-0.37	-0.50	-0.24	-0.41
2021-03-31	-0.49	-0.75	-0.42	-0.16	-0.35
2020-12-31	-0.72	-1.05	-0.36	0.02	-0.15
2020-09-30	-0.59	-0.83	-0.31	0.10	-0.09

Gross Margins

The gross margin for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is 0.20.
The net margin for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is -0.39.
The operating margin for Adaptimmune Therapeutics plc - Depositary Receipt (Common Stock) as of June 30, 2025 is -0.26.

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30	0.20	-0.39	-0.26
2025-03-31	0.16	-0.40	-0.29
2024-12-31	0.18	-0.25	-0.22
2024-09-30	-0.04	-0.51	-0.53
2024-06-30	-6.42	-8.90	-10.61
2024-03-31	-1.10	-1.89	-2.29
2023-12-31	0.68	-1.34	-1.59
2023-09-30	-0.58	-1.29	-1.55
2023-06-30	-0.64	-1.29	-1.55
2023-03-31	-3.70	-1.60	-1.52
2022-12-31	-6.65	-9.98	-10.24
2022-09-30	-10.01	-9.98	-10.24
2022-06-30	-12.28	-15.00	-15.24
2022-03-31	-17.07	-18.36	-18.77
2021-12-31	-16.22	-25.71	-26.39
2021-09-30	-15.58	-25.00	-25.17
2021-06-30	-15.58	-23.92	-24.19
2021-03-31	-25.11	-38.47	-38.98
2020-12-31	-22.13	-32.87	-33.71
2020-09-30	-26.06	-38.58	-39.65